Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EBITDA (2022 - 2025)

Historic EBITDA for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$15.3 million.

  • Phathom Pharmaceuticals' EBITDA rose 7842.96% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.5 million, marking a year-over-year increase of 2585.74%. This contributed to the annual value of -$277.5 million for FY2024, which is 6583.81% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported EBITDA of -$15.3 million as of Q3 2025, which was up 7842.96% from -$59.9 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' EBITDA registered a high of -$15.3 million during Q3 2025, and its lowest value of -$78.9 million during Q1 2025.
  • Moreover, its 4-year median value for EBITDA was -$46.6 million (2022), whereas its average is -$51.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 14384.09% in 2024, then surged by 7842.96% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' EBITDA (Quarter) stood at -$46.6 million in 2022, then crashed by 49.81% to -$69.9 million in 2023, then grew by 14.97% to -$59.4 million in 2024, then surged by 74.3% to -$15.3 million in 2025.
  • Its EBITDA was -$15.3 million in Q3 2025, compared to -$59.9 million in Q2 2025 and -$78.9 million in Q1 2025.